Bangladesh - English - DGDA (Directorate General of Drug Administration)

nipa pharmaceuticals ltd. - paracetamol - suspension - 120 mg/5 ml

Bangladesh - English - DGDA (Directorate General of Drug Administration)

nipa pharmaceuticals ltd. - paracetamol - tablet - 500 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

nipa pharmaceuticals ltd. - paracetamol - paediatric drops - 80 mg/ml

United States - English - NLM (National Library of Medicine)

ge healthcare - iohexol (unii: 4419t9mx03) (iohexol - unii:4419t9mx03) - iodine 300 mg in 1 ml - omnipaque imaging bulk package is indicated for - computed tomographic (ct) imaging of the head and body by intravenous administration in: adults (300 and 350 mg iodine/ml) pediatric patients (300 mg iodine/ml) - adults (300 and 350 mg iodine/ml) - pediatric patients (300 mg iodine/ml) for use only with an automated contrast injection system, contrast management system, or contrast media transfer set cleared for use with omnipaque imaging bulk package. none. risk summary postmarketing data with omnipaque use in pregnant women are insufficient to determine if there is a drug-associated risk of adverse developmental outcomes. iohexol crosses the placenta and reaches fetal tissues in small amounts (see data). in animal reproduction studies, no adverse developmental effects were observed following intravenous iohexol administration to pregnant rats and rabbits during organogenesis at doses up to 0.4 (rat) and 0.5 (rabbit) times the maximum recommended human intravenous dose (see data) . the estimated background

United States - English - NLM (National Library of Medicine)

ge healthcare inc. - iohexol (unii: 4419t9mx03) (iohexol - unii:4419t9mx03) - iodine 300 mg in 1 ml - omnipaque 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography). omnipaque should not be administered to patients with a known hypersensitivity to iohexol. myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. intrathecal administration of corticosteroids with omnipaque is contraindicated. because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see dosage and administration). omnipaque 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels, p

United States - English - NLM (National Library of Medicine)

ge healthcare - iohexol (unii: 4419t9mx03) (iohexol - unii:4419t9mx03) - omnipaque imaging bulk package is indicated for - computed tomographic (ct) imaging of the head and body by intravenous administration in: adults (300 and 350 mg iodine/ml) pediatric patients (300 mg iodine/ml) - adults (300 and 350 mg iodine/ml) - pediatric patients (300 mg iodine/ml) for use only with an automated contrast injection system, contrast management system, or contrast media transfer set cleared for use with omnipaque imaging bulk package. none. risk summary postmarketing data with omnipaque use in pregnant women are insufficient to determine if there is a drug-associated risk of adverse developmental outcomes. iohexol crosses the placenta and reaches fetal tissues in small amounts (see data). in animal reproduction studies, no adverse developmental effects were observed following intravenous iohexol administration to pregnant rats and rabbits during organogenesis at doses up to 0.4 (rat) and 0.5 (rabbit) times the maximum recommended human intravenous dose ( see data ). t

United States - English - NLM (National Library of Medicine)

ge healthcare inc. - iohexol (unii: 4419t9mx03) (iohexol - unii:4419t9mx03) - omnipaque 300 is indicated for intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography). omnipaque should not be administered to patients with a known hypersensitivity to iohexol. myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. intrathecal administration of corticosteroids with omnipaque is contraindicated. because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see dosage and administration). omnipaque 350 is indicated in adults for angiocardiography (ventriculography, selective coronary arteriography), aortography including studies of the aortic root, aortic arch, ascending aorta, abdominal aorta and its branches, intravenous digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 518 mg/ml (equivalent: iodine, qty 240 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 647 mg/ml (equivalent: iodine, qty 300 mg/l) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 388 mg/ml (equivalent: iodine, qty 180 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - intrathecal: omnipaque is indicated for lumbar, thoracic, cervical and total columnar myelography and in computerised tomography of the cns in adults and children. indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.